PILOT TRIAL OF BRANCHED-CHAIN AMINOACIDS IN AMYOTROPHIC LATERAL SCLEROSIS

Adreas Plaitakis, John Mandeli, Jeffrey Smith, Melvin D. Yahr

Research output: Contribution to journalArticlepeer-review

89 Scopus citations

Abstract

22 patients with amyotrophic lateral sclerosis were entered into a double-blind, randomised, placebo-controlled trial of treatment with branched-chain aminoacids. 11 received daily 12 g L-leucine, 8 g L-isoleucine, and 6·4 g L-valine, by mouth, and the remainder received placebo. During the one-year trial, patients in the placebo group showed a linear decline in functional status consistent with the natural history of the disease. Those treated with aminoacids showed significant benefit in terms of maintenance of extremity muscle strength and continued ability to walk.

Original languageEnglish
Pages (from-to)1015-1018
Number of pages4
JournalThe Lancet
Volume331
Issue number8593
DOIs
StatePublished - 7 May 1988

Fingerprint

Dive into the research topics of 'PILOT TRIAL OF BRANCHED-CHAIN AMINOACIDS IN AMYOTROPHIC LATERAL SCLEROSIS'. Together they form a unique fingerprint.

Cite this